Journal Mobile Options
Table of Contents
Vol. 124, No. 1-3, 2001
Issue release date: January–March 2001
Int Arch Allergy Immunol 2001;124:155–157

Further Characterization of FcγRII and FcγRIII Expression by Cultured Human Mast Cells

Okayama Y. · Hagaman D.D. · Woolhiser M. · Metcalfe D.D.
Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: We have reported that resting human mast cells exhibit minimal expression for FcγRI, and that interferon-γ will upregulate this expression. The expression of FcγRII and FcγRIII by human mast cells remains to be fully examined. Methods: To investigate FcγRII and FcγRIII expression, we determined mRNA and protein expression of FcγRII and FcγRIII in human peripheral blood CD34+ derived cultured mast cells by RT-PCR and flow cytometry. The expression of FcγRII and FcγRIII in intact and permeabilized mast cells was also compared. We measured histamine release to monitor mast cell degranulation following cross-linking of FcγRII. Results: We found by RT-PCR that resting human mast cells exhibit mRNA for FcγRIIA, FcγRIIb1, FcγRIIb2 and FcγRIII but not FcγRIIC. FACS analysis of Fcγ receptors in intact versus permeabilized mast cells showed expression of FcγRII to be 42.2 ± 3.9% and this was unchanged by permeabilization. FcγRIII protein expression was minimal and this was also unchanged by permeabilization. Aggregation of FcγRII on human mast cells led to no significant degranulation as evidenced by histamine release. Conclusions: In addition to FcγRI expression, human mast cells express FcγRIIA, FcγRIIb1, FcγRIIb2 and FcγRIII mRNA, and significant surface expression of FcγRII. Aggregation of FcγRII on cultured human mast cells in this model was not followed by histamine release.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Okayama Y, Kirshenbaum AS, Metcalfe DD: Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: Up-regulation by IFN-gamma. J Immunol 2000;164:4332–4339.
  2. Katz HR, Arm JP, Benson AC, Austen KF: Maturation-related changes in the expression of Fc gamma RII and Fc gamma RIII on mouse mast cells derived in vitro and in vivo. J Immunol 1990;145:3412–3417.
  3. Lobell RB, Austen KF, Katz HR: Fc gamma R-mediated endocytosis and expression of cell surface Fc gamma RIIb1 and Fc gamma RIIb2 by mouse bone marrow culture-derived progenitor mast cells. J Immunol 1994;152:811–818.
  4. Katz HR, Raizman MB, Gartner CS, Scott HC, Benson AC, Austen KF: Secretory granule mediator release and generation of oxidative metabolites of arachidonic acid via Fc-IgG receptor bridging in mouse mast cells. J Immunol 1992;148:868–871.
  5. Daeron M, Malbec O, Latour S, Arock M, Fridman WH: Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995;95:577–585.
  6. Fong DC, Malbec O, Arock M, Cambier JC, Fridman WH, Daeron M: Selective in vivo recruitment of the phosphatidylinositol phosphatase SHIP by phosphorylated Fc gamma RIIB during negative regulation of IgE-dependent mouse mast cell activation. Immunol Lett 1996;54:83–91.
  7. Ono M, Bolland S, Tempst P, Ravetch JV: Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 1996;383:263–266.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00